Mathilde Cancel

9PUBLICATIONS

27CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (9)

Sort by Publication Date:

|May 26, 2026

Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.

|Sep 04, 2025

Clinical outcome of advanced or recurrent endometrial carcinoma treated with chemotherapy: a French observational retrospective cohort: the ENDOVIE study.

Jerome Alexandre, Philippe Boudier, Elise Lavit

|Aug 21, 2024

Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial.

Karim Fizazi, Gwénaël Le Teuff, Aude Fléchon

|Jun 13, 2024

Treatment breaks in an oncology unit.

Fanny Vareille, François Chaumier, Claude Linassier

|May 20, 2024

Endocrine therapy in advanced high-grade ovarian cancer: real-life data from a multicenter study and a review of the literature.

Marine Aubert, Laurent Mathiot, Hélène Vegas

|May 06, 2024

FASTOCH: Feasibility of Electronic Patient-Reported Outcomes in Older Patients With Cancer-A Multicenter Prospective Study.

Mathilde Cancel, Carine Sauger, Julie Biogeau

Pageof 2

Frequent Collaborators

David Crottès

Pierre Combe

Gwenaëlle Gravis

Mehdi Brahmi

Maud Toulmonde

Emmanuelle Bompas

Francois Le Loarer

Sarah Watson

Gaëlle Fromont

Thierry Lecomte

Frequent Collaborators

David Crottès

Pierre Combe

Gwenaëlle Gravis

Mehdi Brahmi